| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients… | Intracranial Meningioma | Recruiting |
| NCT01267955 | Vismodegib in Treating Patients With Advanced Chondrosarcomas | Clear Cell Chondrosarcoma | Active, Not Recruiting |
| NCT06357988 | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With… | Advanced Lymphoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell… | Metastatic Lung Non-Small Cell Carcinoma | Recruiting |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in… | Adult Solid Neoplasm | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT05651828 | Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma | Advanced Basal Cell Carcinoma | Recruiting |